A Study of Psilocybin for PTSD

Status Recruiting

Clinical Trial Summary

The proposed open-label, controlled study at the Johns Hopkins Center for Psychedelic and Consciousness Research (CPCR) will test the following primary hypotheses in adult patients with chronic PTSD who are currently taking a serotonin reuptake inhibitor: psilocybin therapy will be feasible and safe for participants, significantly remediate PTSD symptoms, and enhance wellbeing and quality of life. In addition, the study will examine whether elements of evidence-based trauma-focused psychotherapy enhance treatment response when paired with psilocybin.

Clinical Trial Description

This study uses a randomized controlled design to compare the safety and efficacy of 2 doses of psilocybin for PTSD. In addition, it will investigate the effects of trauma-focused psychotherapy (which includes standard psychological support) versus standard psychological support alone. Twenty participants will be recruited. Following the first psilocybin session, participants will be randomized to either the trauma-focused psychotherapy (which includes standard psychological support) treatment condition or the standard psychological support treatment condition (the latter being typical for the experimental administration of psilocybin therapy). Both groups will receive identical treatment prior to receiving the first dose of psilocybin, with one group receiving procedures related to trauma-focused psychotherapy (combined with standard psychological support) beginning after receipt of psilocybin. The study will include clinician and participant ratings of PTSD and mood symptoms pre- and post-drug session and monitor and participant ratings of subjective drug effects during and after each drug session. The intervention for both groups will consist of about 8 hours of preparatory meetings (over approximately 2 weeks), followed by 2 psilocybin sessions separated by approximately 2 weeks. The initial psilocybin dose will be 25 mg. The dose for the second session may be increased conditional on the strength of subjective effects, as measured by the Mystical Experiences Questionnaire (MEQ30), taken at the end of participants' first psilocybin session. This allows a dose to increase if, for example, concomitant serotonin reuptake inhibitors reduce subjective effects. Participants with a score ≥60% of the maximum on the MEQ30 will remain at a dose of 25 mg of psilocybin for the second session. Participants with an MEQ30 score below 60% will receive a dose of 40 mg for the second session. Elevation of dose will also be based on the clinical judgment of the principal investigator, study physician, and study staff that a higher dose can be safely administered. In addition, participants who prefer to not elevate the dose will remain at 25 mg for the second session. To support the participant's therapeutic integration of psilocybin experiences, following each psilocybin session, participants will meet with the session facilitator(s) at multiple scheduled time points. Additional contact hours will be scheduled if it is judged that the participant would benefit from additional meetings to discuss experiences from the session(s) or to prepare for the next session. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT06407635
Study type	Interventional
Source	Johns Hopkins University
Contact	Brandon Weiss, PhD
Phone	410-550-0048
Email	brandon@jhmi.edu
Status	Recruiting
Phase	Phase 1
Start date	June 7, 2024
Completion date	May 2027

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05915013` - Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine Response	Phase 1
Recruiting	`NCT05563805` - Exploring Virtual Reality Adventure Training Exergaming	N/A
Recruiting	`NCT05934175` - Intensive Treatment Versus Standard Weekly Prolonged Exposure for Adults With Post-Traumatic Stress Disorder	N/A
Recruiting	`NCT05934162` - Efficacy of Internet-delivered Cognitive-behavior Therapy for PTSD	N/A
Completed	`NCT04460014` - Simple Cognitive Task Intervention After Trauma During COVID-19 In Hospital Staff EKUT-P RCT	N/A
Completed	`NCT05877807` - Effect of Baclofen to Prevent Post-Traumatic Stress Disorder
Active, not recruiting	`NCT05992649` - The Effect of Aquatic Physiotherapy on Veterans Suffering From PTSD - a 40-week Pilotproject	N/A
Terminated	`NCT04404712` - FAAH Availability in Psychiatric Disorders: A PET Study	Early Phase 1
Not yet recruiting	`NCT05331534` - Effect of Attentional Therapy on Post-traumatic Stress Disorder	N/A
Not yet recruiting	`NCT03649607` - Accelerated Resolution Therapy for HIV Positive African, Caribbean and Black	N/A
Not yet recruiting	`NCT04076215` - Biochemical and Physiological Response to Stressogenic Stimuli	N/A
Not yet recruiting	`NCT02545192` - A Pilot Study of Low Field Magnetic Stimulation in PTSD: Three Daily Treatments	Phase 1
Completed	`NCT02329418` - Written Document to Assist Family During Decision of Withholding and Withdrawing Life-sustaining Therapies in the Intensive Care Unit	N/A
Active, not recruiting	`NCT00978484` - A Head-to-head Comparison of Virtual Reality Treatment for Post Traumatic Stress Disorder	Phase 3
Completed	`NCT00760734` - Hyperbaric Oxygen Therapy (HBOT) in Chronic Traumatic Brain Injury (TBI)/Post Concussion Syndrome (PCS) and TBI/Post-Traumatic Stress Disorder (PTSD)	Phase 1
Completed	`NCT03278171` - Early Detection of Patients at Risk of Developing a Post-traumatic Stress Disorder After a Stay in Intensive Care Unit
Recruiting	`NCT05874362` - People Bereaved by Violent Death : Negative Event Biases and Temporal Perception	N/A
Terminated	`NCT03898843` - Assisted Animal Therapy: ReAnimal	N/A
Recruiting	`NCT04747379` - Psychological Effect of Explicit Recall After Sedation (PEERS)
Completed	`NCT03248167` - Cannabidiol as a Treatment for AUD Comorbid With PTSD	Phase 1/Phase 2